Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4+and CD8+memory formation by Schmied, Sabine et al.
Analysis of the functional WT1-specific T-cell repertoire in healthy
donors reveals a discrepancy between CD4+ and CD8+ memory
formation
Sabine Schmied,1 Emma Gostick,2
David A. Price,2 Hinrich Abken,3,4
Mario Assenmacher1 and Anne
Richter1
1Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany, 2Institute of Infection & Immunity,
Cardiff University School of Medicine, Cardiff,
UK, 3Centre for Molecular Medicine Cologne,
University of Cologne, and 4Department I
Internal Medicine, University Hospital
Cologne, Cologne, Germany
doi:10.1111/imm.12472
Received 20 November 2014; revised 11
March 2015; accepted 31 March 2015.
Correspondence: S. Schmied, Miltenyi Bio-
tec GmbH, Friedrich-Ebert-Strasse 68, Berg-
isch Gladbach 51429, Germany. Email:
s_schmied@hotmail.com
Senior author: Dr Anne Richter
Email: anner@miltenyibiotec.de
Summary
The Wilms’ tumour-1 (WT1) protein is considered a prime target for can-
cer immunotherapy based on its presumptive immunogenicity and wide-
spread expression across a variety of malignancies. However, little is
known about the naturally occurring WT1-specific T-cell repertoire
because self-derived antigens typically elicit low frequency responses that
challenge the sensitivity limits of current detection techniques. In this
study, we used highly efficient cell enrichment procedures based on
CD137, CD154, and pHLA class I tetramer staining to conduct a detailed
analysis of WT1-specific T cells from the peripheral blood. Remarkably,
we detected WT1-specific CD4+ and CD8+ T-cell populations in the vast
majority of healthy individuals. Memory responses specific for WT1 were
commonly present in the CD4+ T-cell compartment, whereas WT1-spe-
cific CD8+ T cells almost universally displayed a naive phenotype. More-
over, memory CD4+ and naive CD8+ T cells with specificity for WT1
were found to coexist in some individuals. Collectively, these findings sug-
gest a natural discrepancy between the CD4+ and CD8+ T-cell lineages
with respect to memory formation in response to a self-derived antigen.
Nonetheless, WT1-specific T cells from both lineages were readily acti-
vated ex vivo and expanded in vitro, supporting the use of strategies
designed to exploit this expansive reservoir of self-reactive T cells for
immunotherapeutic purposes.
Keywords: antigen-specific T cells; self-antigen; tumour-associated antigen;
Wilms’ tumour-1 protein.
Introduction
The Wilms’ tumour-1 (WT1) protein is a transcription
factor expressed at high levels in several haematological
malignancies and some solid tumours. As a consequence
of its oncogenic potential and presumptive immunogenic-
ity, WT1 was ranked top in a list of tumour-associated
antigens prioritized for cancer immunotherapy.1 Indeed,
spontaneous T-cell responses against WT1 are induced in
patients with leukaemia after allogeneic stem cell trans-
plantation or donor lymphocyte infusions2–4 and are
associated with disease regression.4 WT1-specific T cells
may also be involved in cancer immune surveillance.
However, little is known about the naturally occurring
WT1-specific T-cell repertoire and its functional relevance
in vivo, in part because of the exceedingly low frequencies
of such cells in healthy donors. This knowledge gap
potentially hinders the rational development of an effec-
tive WT1-directed T-cell therapy.
WT1-specific CD8+ T cells have been detected ex vivo
in myeloid leukaemia patients by peptide-HLA class I
(pHLAI) tetramer staining5 and by quantitative PCR for
interferon-c (IFN-c) mRNA after antigenic stimulation,
revealing elevated frequencies following stem cell trans-
plantation.6,7 Highly sensitive IFN-c mRNA analysis also
provided the first hint that such cells exist in healthy
Abbreviations: ARTE, antigen-reactive T-cell enrichment; WT1, Wilms’ tumour-1
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individuals, although detailed characterization was pre-
cluded by technical constraints at the detection limit.6,7
Similar issues hamper the reliable detection of auto-reac-
tive and tumour-associated antigen-specific T cells in
healthy donors by other methods, including IFN-c ELI-
Spot analysis and pHLAI tetramer staining. As an excep-
tion, Melan-A/MART-1-specific CD8+ T cells can be
detected at high frequencies in the naive repertoire of
healthy individuals.8,9
To detect T cells specific for self-derived antigens other
than Melan-A/MART-1 ex vivo in healthy donors, addi-
tional strategies must be employed to overcome the sensi-
tivity limits of conventional methods. Magnetic
enrichment of pHLAI tetramer+ cells has been imple-
mented successfully in this regard to detect rare NY-ESO-
1-specific CD8+ T cells10 and gp100-specific CD4+ T
cells.11 In addition, surface molecules up-regulated after
antigenic stimulation allow the visualization of activated
antigen-specific T cells. For example, CD154 (CD40L) is
expressed within a few hours after antigenic stimulation
of CD4+ T cells. This approach has been used successfully
in conjunction with antigen-specific enrichment to detect
WT1-specific T cells ex vivo in healthy donors; the fre-
quencies of these cells were calculated to range from 106
to 105 within the CD4+ T-cell compartment.12 The acti-
vation marker CD137 (4-1BB) further enables the detec-
tion of antigen-specific CD4+ and CD8+ T cells from the
naive and memory pools.13 However, stimulation for
more than 24 hr is required to induce CD137 on naive T
cells, potentially distorting the phenotypic composition of
activated cells acquired with this approach.
In this study, we used enrichment techniques based on
pHLAI tetramer staining and the up-regulation of activa-
tion markers to characterize the entire WT1-specific T-cell
repertoire functionally and phenotypically in a compre-
hensive and highly sensitive manner. Our approach incor-
porated multi-colour flow cytometric analysis directly
ex vivo or after short-term in vitro expansion. Virtually all
healthy donors harboured WT1-specific T cells in their
peripheral blood. In the CD4+ cell compartment, memory
T cells specific for WT1 were detected in 60% of cases. In
contrast, WT1-specific CD8+ T cells retained a naive phe-
notype in the vast majority of donors. These findings
highlight a natural discrepancy between the CD4+ and
CD8+ T-cell lineages with respect to memory formation
in response to a self-derived antigen.
Materials and methods
Isolation of peripheral blood mononuclear cells
Buffy coats or leukapheresis products were obtained from
healthy donors at the University Hospital in Dortmund
and Cologne. The study was performed according to
established ethical guidelines and all blood donors gave
informed consent. Peripheral blood mononuclear cells
(PBMCs) were isolated using Ficoll–Hypaque (GE Health-
care, Chalfont St Giles, UK) density gradient centrifuga-
tion.
Stimulation, isolation, and expansion of antigen-specific
T cells
Freshly isolated PBMCs were resuspended in RPMI-1640
medium supplemented with 5% human AB serum (Lonza,
Basel, Switzerland), 2 mM L-glutamine (GE Healthcare),
and 1 µg/ml CD28 monoclonal antibody (mAb) at func-
tional grade purity (Miltenyi Biotec, Bergisch Gladbach,
Germany). Subsequently, 1 9 108 PBMCs were stimulated
at 1 9 107 cells/ml with the optimal WT1126 peptide
(RMFPNAPYL) and pooled WT1 15-mer peptides, over-
lapping by 11 amino acids, covering the whole WT1 iso-
form-1 protein sequence (Miltenyi Biotec); each peptide
was present at a final concentration of 06 nmol/ml.
Controls in the absence of exogenous peptide were
included in all cases.
For ex vivo characterization of WT1-specific CD4+ T
cells, PBMCs were stimulated for 7 hr in the presence of
1 µg/ml CD40 mAb at functional grade purity (Miltenyi
Biotec). Brefeldin A (1 µg/ml; Sigma-Aldrich, St Louis,
MO) was added 2 hr before harvest. CD154+ cells were
isolated by indirect magnetic labelling using CD154-allo-
phycocyanin and anti-allophycocyanin-MicroBeads (Milt-
enyi Biotec). Samples were loaded on MS Columns
(Miltenyi Biotec) and intracellular staining was performed
directly in the magnetic field using an Inside Stain Kit
(Miltenyi Biotec). Frequencies of WT1-specific CD4+ T
cells were calculated by subtracting the mean number of
CD4+ CD154+ cells (triplicates) obtained after enrichment
of non-stimulated PBMCs from the mean number of
CD4+ CD154+ cells (triplicates) obtained after enrichment
of WT1 peptide-stimulated PBMCs and dividing by the
total number of CD4+ T cells applied to the column. A
positive WT1-specific response was recorded if the mean
CD4+ CD154+ count after WT1 peptide pool stimulation
exceeded the 95% confidence interval for the
CD4+ CD154+ count in the unstimulated sample (mean
plus two times the standard error of the mean).
Antigen-reactive CD4+ and CD8+ T cells were isolated
after 24–36 hr using a CD137 MicroBead Kit (Miltenyi
Biotec) and expanded in X-Vivo15 (Lonza) supplemented
with 5% human AB serum (Lonza), 5 ng/ml recombinant
interleukin-7 (rIL-7), 5 ng/ml rIL-15, and 10 ng/ml rIL-
21 (all Miltenyi Biotec). The corresponding CD137 cell
fractions were depleted of CD3+ cells using CD3-Mi-
croBeads (Miltenyi Biotec), treated with mitomycin C
(Sigma-Aldrich), and co-cultured as peptide-loaded autol-
ogous antigen-presenting cells (APCs) with activated T
cells at a ratio of 100 : 1 with a final density of
5 9 106 cells/ml in 24-well plates. Medium, including the
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recombinant cytokines, was replenished every second day.
Cells were washed and counted on day 6 and then
expanded for a further 3 days.
Re-stimulation of expanded antigen-specific T cells
Two days before re-stimulation, cells were washed and
plated at a concentration of 25 9 106 cells/ml in cyto-
kine-free medium. Thawed autologous CD3-depleted
PBMCs were pulsed with pooled peptides (06 nmol/ml/
peptide) overnight, washed once, and co-cultured as
APCs at a ratio of 1 : 5 with expanded T cells in RPMI-
1640 medium supplemented with 5% human AB serum
and 1 µg/ml CD28 mAb at functional grade purity in 96-
well plates for 6 hr. Brefeldin A (1 µg/ml) was added
after 2 hr of co-culture. For assessment of degranulation,
co-cultures were supplemented with CD107a-PE (phyco-
erythrin; Miltenyi Biotec) and 1 µg/ml monensin (eBio-
science, San Diego, CA). Cells were then fixed,
permeabilized, and stained intracellularly using a Rapid
Cytokine Inspector (Miltenyi Biotec).
For determination of functional avidity, T2 cells were
pulsed overnight with escalating doses of the optimal
WT137 peptide (VLDFAPPGA) and co-cultured with
expanded T cells at a ratio of 1 : 25 before staining as
described above. For measurement of direct cytotoxicity,
T2 cells were either pulsed with peptide pools (specific:
WT1; unrelated: HPV16 E7; Miltenyi Biotec) or left un-
pulsed overnight, labelled with different concentrations of
VioDye (Invitrogen, Carlsbad, CA) for 5 min at 37°C,
washed three times, and pooled. Labelled T2 cell pools
were then added to expanded T cells at different effector
to target (E : T) ratios for 4 hr. For blocking experi-
ments, 1 µg/ml anti-MHCI mAb (W6/32) was added to
the co-culture. Antigen-specific killing was determined by
flow cytometric measurement of T2 cell viability. Percent-
age killing was calculated by subtracting the ratio of living
antigen-loaded T2 cells after co-culture in the presence or
absence of T cells from unity. Percentage antigen-specific
killing was calculated by subtracting killing determined
for non-loaded T2 cells from killing determined for anti-
gen-loaded T2 cells.
Flow cytometry
The following mAbs were used for staining and flow cyto-
metric measurements: CD3-VioGreen (BW264/56), CD4-
allophycocyanin-Vio770 (VIT4), CD8-PE-Vio770 (BW135/
80), CD14-peridinin chlorophyll protein (PerCP) (T€UK4),
CD20-PerCP (LT20), CD27-FITC (M-T271), CD28-FITC
(15E8), CD45RA-VioBlue (T6D11), CD45RO-FITC
(UCHL1), CD62L-FITC (145/15), CD107a-PE (1D4B),
CD127-FITC (MB15-18C9), CD137-allophycocyanin,
CD137-PE (4B4-1), CD154-VioBlue (5C8), CD178-PE
(NOK-1), CD197 (CCR7)-allophycocyanin, CD197
(CCR7)-PE (150503), CD279-allophycocyanin (PD1.3.1.3),
anti-IL-2-PE-Vio770 (N7.48A), anti-IL-4-PE (7A3-3), anti-
IL-17-FITC (CZ8-23G1), anti-IFN-c-FITC, anti-IFN-c-PE-
Vio770 (45-15), anti-TNF-a-PE, and anti-TNF-a-VioBlue
(cA2) (all Miltenyi Biotec).
Soluble biotinylated pHLA-A*0201 molecules loaded
with WT137 (VLDFAPPGA), WT1126 (RMFPNAPYL),
WT1187 (SLGEQQYSV), WT1235 (CMTWNQMNL), or
cytomegalovirus (CMV) pp65495 (NLVPMVATV) were
produced as described previously.14 Tetramerization was
achieved by binding to streptavidin-PE or streptavidin-all-
ophycocyanin (both BioLegend, San Diego, CA). In each
case, 25 9 106 cells were stained with 1 µg/ml tetramer
for 45 min at 4°C.
Data were acquired using a MACSQuant flow cytome-
ter and analysed with MACSQuantify software (both
Miltenyi Biotec).
Sorting of T-cell subsets
Freshly isolated PBMCs from leukapheresis products were
used for all T-cell subset purifications. Naive T cells were
sorted at > 99% purity using a human Naive Pan T Cell
Isolation Kit (Miltenyi Biotec). Memory T cells were
sorted using a human Pan T Cell Isolation Kit (Miltenyi
Biotec) and additionally depleted of CD45RA+ cells using
CD45RA-MicroBeads (Miltenyi Biotec). Sorted T cells
(1 9 108) were supplemented with 1 9 107 APCs and
pooled peptides for stimulation.
Enrichment of tetramer+ cells
For antigen-specific T-cell enrichment, 1 9 108 Pan
T cells were labelled with PE-conjugated WT137 tetramer
(05 µg/ml) for 15 min at 37°C. Allophycocyanin-conju-
gated WT137 tetramer (1 µg/ml) and mAbs were then
added for 15 min at 4°C. After washing, cells were incu-
bated with anti-PE-MicroBeads (Miltenyi Biotec) for
15 min at 4°C and washed again. Separation was per-
formed using two subsequent MS columns according to
the manufacturer’s protocol (Miltenyi Biotec). The posi-
tive fraction was analysed directly using a MACSQuant
flow cytometer (Miltenyi Biotec). Cells were gated hierar-
chically as follows: lymphocytes, singlets, viable cells,
CD14 and CD20, CD3+, and CD8+. Frequencies of
WT137-specific CD8
+ T cells were determined by dividing
the number of WT137 tetramer-PE/allophycocyanin dou-
ble-positive CD8+ T cells by the number of total CD8+
cells applied to the column.
Statistics
The paired Student’s t-test was used to assess significance.
Analyses were conducted using PRISM software version 6.0
(GraphPad, San Diego, CA).
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Results
Functionally competent WT1-specific T cells can be
efficiently propagated in vitro from healthy donors
To assess WT1-specific T cells in the peripheral blood of
healthy donors, we stimulated PBMCs with a WT1 pep-
tide mix for 24–36 hr and subsequently enriched CD137+
cells. CD137 (4-1BB) is up-regulated upon T-cell receptor
(TCR) engagement and was previously used to detect
antigen-specific memory and naive CD4+ and CD8+ T
cells.13,15
Flow cytometric analysis of the enriched cell fractions
revealed significantly elevated numbers of CD4+ CD137+
and CD8+ CD137+ T cells in WT1-stimulated PBMC
samples compared with unstimulated controls (see Sup-
plementary material, Fig. S1). Absolute cell numbers
after enrichment ranged from 12 9 104 to 43 9 104
(mean 33 9 104) viable CD137+ leucocytes in the
stimulated samples compared with 09 9 104 to
32 9 104 (mean 25 9 104) cells in the control sam-
ples (see Supplementary material, Fig. S1b). This direct
numeric comparison suggests that the majority of
enriched T cells in the WT1-stimulated samples were
pre-activated in vivo by antigens other than WT1. To
demonstrate the presence of WT1-reactive T cells in
the CD137+ fraction and obtain sufficient cell numbers
for further characterization, we expanded the enriched
cell populations for 9 days in vitro (see Supplementary
material, Fig. S1c).
Tetramer staining confirmed the antigen specificity of
expanded T cells in the CD8+ compartment (Fig. 1a). In
21/24 HLA-A2+ samples, WT1-specific cells were detected
by at least one of four pHLA-A*0201 tetramers based on
the previously described epitopes WT137, WT1126,
WT1187,
16 and WT1235.
17 The WT137 epitope was both
immunodominant (05–30% within CD8+) and immuno-
prevalent (18/24 samples). Moreover, in 10/18 samples
with WT137 reactivity, at least one additional tetramer
+
population was recorded. Further WT1 specificities may
exist within the expanded repertoire, including reactivities
beyond the context of HLA-A*0201. Notably, two specific
populations with heterogeneous staining intensities were
observed with one tetramer in some cases. These data
imply differential avidities for cognate antigen, potentially
reflecting either distinct clonotype usage or alternative
activation states.18,19
Functional characterization of the expanded T-cell frac-
tions further confirmed their specificity for WT1. After
short-term re-stimulation with WT1 peptide pool-loaded
autologous APCs, substantial proportions of WT1-reac-
tive T cells produced IFN-c and tumour necrosis factor-a
(TNF-a) and expressed the activation markers CD137
and CD154 (Fig. 1b,c). Minimal responses were observed
with control APCs, although IFN-c production by CD4+
T cells occurred at frequencies up to 48% in 12/30
donors. Antigen-specific cytokine production was
detected in all cultures obtained from healthy donors
after stimulation. Mean frequencies for TNF-a production
were 124% for CD4+ T cells (range 2–59%) and 64%
for CD8+ T cells (range 05–34%). The corresponding fre-
quencies for IFN-c production were 60% (range 05–
36%) and 51% (range 05–23%) of T cells, respectively.
Each donor harboured lymphocytes with a WT1-induced
cytokine response in the CD4+ and/or CD8+ T-cell
compartment.
Cytokine production correlated with activation marker
expression. Mean frequencies for WT1-induced CD137
up-regulation were 4.9% for CD4+ T cells (range 0.5–
35%) and 7.3% for CD8+ T cells (range 0.5–45%). The
corresponding frequencies for CD154 expression were
112% (range 15–50%) and 24% (range 02–30%),
respectively. CD154 expression levels on CD8+ T cells
were low compared with cytokine production. This obser-
vation is consistent with previous reports in the context
of CD4+ T cells.20 Notably, WT1-specific cytokine
production was also detected in all three donors lacking
tetramer+ populations.
Expanded WT1-specific T cells mobilized CD107a
after antigen encounter, indicating antigen-induced
degranulation and lytic potential (see Supplementary
material, Fig. S2a). This was also marked for CD4+ T
cells, consistent with previous reports.21 Direct cytotox-
icity against WT1 peptide-loaded T2 cells was also
recorded for CD8+ T cells (see Supplementary material,
Fig. S2b), indicating the potential for a WT1-driven
cytolytic attack.
Phenotypic analyses after short-term expansion showed
that the majority of tetramer+ WT1-specific T cells
expressed CD27, CD28, and CD127 within a predominant
CD45RO+ CCR7 effector memory phenotype. These
cells did not express CD57, CD178, or CD279, implying a
lack of senescence and exhaustion.
Collectively, these data show that WT1-reactive CD4+
and CD8+ T cells are present in the peripheral blood of
virtually all healthy donors. Furthermore, these cells are
amenable to expansion while retaining their functional
and phenotypic assets in vitro.
WT1-reactive memory CD4+ T cells are present in
the majority of healthy donors
To enumerate and characterize rare, pre-existing WT1-
specific CD4+ T cells in healthy donors directly ex vivo,
we used a previously reported antigen-reactive T-cell
enrichment (ARTE) protocol.12 In brief, the approach
enables the analysis of antigen-specific CD4+ T cells at
frequencies as low as 106 by magnetic enrichment of
CD154+ cells after stimulation of 107–108 PBMCs. As
CD154 is up-regulated within a few hours after TCR
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ligation, it allows simultaneous quantification and func-
tional characterization of the antigen-reactive CD4+ T-cell
pool.
Numbers of CD4+ CD154+ T cells increased substan-
tially after stimulation of PBMCs with WT1 peptides
(mean 190 cells, range 50–555 cells) compared with
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unstimulated control samples (mean 87 cells, range 27–
198 cells) in 22/24 donors (Fig. 2a). On the basis of the
WT1-specific CD154+ cell count after stimulation and the
overall number of CD4+ T cells in each sample, WT1-
reactive T-cell frequencies were calculated to range
between 2 9 106 and 2 9 105 within the CD4+ T-cell
compartment.
Intracellular TNF-a staining of enriched CD154+ cells
was performed directly in a magnetic field to minimize
cell loss12 (Fig. 2b). WT1-induced TNF-a-producing
CD4+ T cells were detected in 21/24 samples (3–228
CD154+ TNF-a+ cells in WT1-stimulated samples versus
0–32 CD154+ TNF-a+ cells in unstimulated controls).
Frequencies ranged between 2 9 107 and 1 9 105
within the CD4+ T-cell compartment.
As these results imply considerable individual varia-
tion in the frequencies of detectable WT1-reactive
CD154+ and CD154+ TNF-a+ cells, we conducted a
more detailed phenotypic and functional analysis. Spe-
cifically, we evaluated CD45RO, CD45RA, and CCR7
expression in one sample along with TNF-a and IFN-c
production in a parallel sample from the same donor.
In some individuals, we also evaluated the production
of IL-2, IL-4, IL-10, and IL-17. Based on the pheno-
typic data, we divided the 20 analysed donors into two
groups: (i) those with WT1-reactive naive and memory
cells (n = 13); and (ii) those with WT1-reactive naive
cells only (n = 7).
In the ‘memory response’ group, higher numbers of
naive (CD45RO CCR7+) and memory (CD45RO+
CCR7+/) CD154+ T cells were present after WT1 stimu-
lation compared with the corresponding unstimulated
samples (Fig. 2c). Moreover, at least 15-fold higher num-
bers of CD154+ cells were detected after enrichment in
the WT1-stimulated samples compared with unstimulated
controls. Ten or more CD154+ TNF-a+ events were
detected in these samples. The frequency of TNF-a+ cells
within the CD154+ compartment was generally higher
compared with the ‘no memory response’ group (mean
296%, range 141–536%) (Fig. 2f). The memory pheno-
type of cytokine-producing WT1-specific T cells was
confirmed by co-staining for CD45RO, CCR7, TNF-a,
and IFN-c in three additional healthy donors (Fig. 2e).
Although WT1-specific TNF-a-producing cells predomi-
nantly expressed CD45RO, functional cells with a naive
phenotype were also detected. In contrast, IFN-c
producers resided exclusively in the memory
compartment. Notably, IL-2-producing cells were
detected in 5/7 donors, IFN-c production was detected in
5/14 donors and IL-17 production was detected in 1/7
donors.
In the ‘no memory response’ group, small numbers of
WT1-specific CD154+ TNF-a+ cells were present (2 to 8
CD154+ TNF-a+ events above background) in 4/7 donors.
All CD154+ events recognized above background dis-
played a naive CD45RO CCR7+ phenotype (Fig. 2d).
No WT1-induced production of IL-4 or IL-10 was
observed. WT1-specific CD8+ CD154+ T cells were not
detected (data not shown).
These data confirm that functional WT1-specific CD4+
T cells are present in all healthy donors and further
demonstrate that the majority (> 60%) of healthy donors
harbour a memory CD4+ T-cell pool specific for WT1.
WT1-specific CD8+ T cells derive predominantly from
the naive pool in healthy donors
To investigate the ex vivo phenotype of WT1-specific
CD8+ T cells, we performed magnetic enrichment of
WT137 tetramer
+ cells directly from HLA-A2+ healthy
donor-derived PBMCs. The WT137 epitope was chosen
for these experiments as this epitope is the most abun-
dant specificity after CD137 enrichment (Fig. 1a). Across
16 samples, CD8+ tetramer+ events ranged from 1 to 55
cells (mean 14 cells). Two internal control mechanisms
were employed to eliminate non-specific background
staining.22 First, dual labelling was performed with the
WT137 tetramer conjugated to allophycocyanin or PE.
Enrichment was then performed using anti-PE-MicroBe-
ads and only double-positive events were recorded as
antigen-specific. Second, concomitant staining of CD4+ T
cells was used as a reference standard (Fig. 3a). For enu-
meration and phenotypic analysis, we included samples
with at least five CD8+ tetramer+ events (n = 10). Using
this approach, frequencies of WT137-specific T cells ran-
ged from 3 9 107 to 3 9 106 (mean 1 9 106) within
Figure 1. Functionally competent, oligoclonal Wilms’ tumour-1 (WT1)-specific CD4+ and CD8+ effector T cells can be generated from healthy
donors. Peripheral blood mononuclear cells (1 9 108) were stimulated with pooled, overlapping WT1 15-mer peptides for 24–36 hr, enriched for
CD137+ cells, and expanded for 9 days. (a) Frequencies of WT1 tetramer+ cells specific for four different HLA-A*0201-restricted epitopes within
the CD8+ T-cell compartment (n = 24; 10 independent experiments were performed; n.d., not detected). Dot plots show representative stainings
of expanded T cells from one donor with the indicated tetramers (CMV pp65495 was used as a negative control). (b, c) Intracellular staining for
interferon-c (IFN-c), tumour necrosis factor-a (TNF-a), CD137, and CD154 expression after re-stimulation of expanded T-cell cultures for 6 hr
with autologous unloaded antigen-presenting cells (APCs) or APCs loaded with WT1 peptides. (b) Dot plots show representative stainings of one
T-cell culture. Frequencies within the CD4+ or CD8+ T-cell compartment are depicted. (c) Frequencies of CD4+ and CD8+ T cells that produce
cytokines or express activation markers after re-stimulation (n = 30; 12 independent experiments were performed). T-cell frequencies after co-
incubation with unloaded APCs were subtracted. Bar represents mean.
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the CD8+ T-cell compartment (Fig. 3b). Moreover, the
vast majority of these WT137-specific CD8
+ T cells (70–
100%) displayed a naive CD45RA+ CCR7+ phenotype
(Fig. 3a,c). We conclude that the majority of WT137-spe-
cific CD8+ T cells detected in healthy donors emanate
from the naive pool.
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Phenotypic disparity between CD4+ and CD8+ T cells
specific for WT1
Ex vivo characterization of WT1-reactive CD4+ T cells
using the ARTE protocol revealed a high proportion of
donors with antigen-specific memory responses in the
periphery. In contrast, the majority of WT1-specific
CD8+ T cells detected ex vivo by WT137 tetramer enrich-
ment exhibited a naive phenotype.
To evaluate the in vivo phenotypic origin of WT1-spe-
cific CD8+ T cells across further specificities, we pre-
sorted T-cell subsets before stimulation. This approach
allows the simultaneous detection of WT1-reactive CD4+
and CD8+ T cells and determination of their phenotype
in one sample. Naive CD45RA+ CCR7+ and memory
CD45RO+ T cells were sorted by magnetic cell separation
in an untouched manner from five sets of donor PBMCs.
In all cases, subset purity was > 99% within the CD3+
compartment (data not shown). Subset-defined T cells
(05 9 108 to 1 9 108) were then stimulated with pooled
WT1 peptides and autologous CD3-depleted APCs for
36 hr, sorted on the basis of CD137 expression and
expanded. Tetramer analysis was used to evaluate the
HLA-A2+ samples (donors 2, 4, and 5). In all three cases,
tetramer+ cells were detected in T-cell cultures derived
from the naive pool but not from the memory pool, sug-
gesting that WT137-specific CD8
+ T cells emanate from
the naive repertoire in healthy donors (Fig. 4a). WT1-
specific CD8+ T cells were also recorded by staining with
mixed tetramers in the unsorted fractions, which were
stimulated and enriched for CD137+ cells. No tetramer+
cells were detected in either T-cell fraction without
previous enrichment due to methodological sensitivity
Before
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Figure 3. The majority of WT137-specific
CD8+ T cells exhibit a naive phenotype. WT137
tetramer+ cells were enriched from 08 9 108
to 12 9 108 T cells using anti-phycoerythrin-
MicroBeads. (a) Dot plots show representative
enrichment of WT137 tetramer
+ cells. Dual
staining with WT137 tetramers is shown for
CD8+ and CD4+ cells. Percentages within the
CD8+ T-cell compartment and total counts of
double-positive cells are shown. Stainings for
CD45RA and CCR7 are shown for CD8+ tetra-
mer+ cells and all CD8+ cells. (b) Frequencies
of CD8+ tetramer+ cells within the CD8+ com-
partment for 10 HLA-A2+ donors (6 indepen-
dent experiments were performed). (c)
Frequencies of CD45RA+ cells within WT137-
specific CD8+ tetramer+ cells (n = 10; 6 inde-
pendent experiments were performed).
Figure 2. Wilms’ tumour-1 (WT1)-specific memory CD4+ T cells are detected in the majority of healthy donors. Peripheral blood mononuclear
cells were incubated with or without pooled WT1 peptides for 7 hr and then enriched for CD154+ cells. (a) Cell count (n) of CD4+ CD154+ cells
after enrichment of CD154+ cells in unstimulated (w/o) and WT1-stimulated (WT1) samples (n = 24; means of at least two technical replicates
are depicted; 12 independent experiments were performed). Bar represents mean; significance was determined using a paired Student’s t-test. (b)
Cell count (n) of CD4+ CD154+ TNF-a+ cells after enrichment of CD154+ cells in unstimulated (w/o) and WT1-stimulated (WT1) samples. Bar
represents mean; significance was determined using a paired Student’s t-test. (c, d) Dot plots (left) and enumeration (right) of flow cytometric
stainings for tumour necrosis factor-a (TNF-a) and CD4+ CD154+ cell phenotype. Enriched CD4+ CD154+ cells, subdivided phenotypically into
CD45RO CCR7+ naive, CD45RO+ CCR7+ central memory (TCM), CD45RO
+ CCR7 effector memory (TEM), and CD45RO
 CCR7 terminally
differentiated effector (TEM-RA) T cells or functionally according to cytokine expression were enumerated in unstimulated (w/o) and WT1-stimu-
lated (WT1) samples. Total cell counts obtained from 5 9 107 peripheral blood mononuclear cells for donors with (c) or without (d) a memory
CD4+ T-cell response are shown. Significance was determined using a paired Student’s t-test and defined as: *P < 005, **P < 001,
***P ≤ 0001, n.s. = not significant. (e) Dot plots show a representative staining of WT1-stimulated cells producing TNF-a and interferon-c
(IFN-c) from the blood of a single donor with a memory response against WT1 (n = 3 donors). (f) Frequencies of TNF-a-producing cells within
WT1-reactive CD4+ CD154+ cells (n = 24; 12 independent experiments were performed). Background cell counts detected in the corresponding
unstimulated samples were subtracted.
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limitations. Collectively, these data support the conclu-
sion that WT1-reactive CD8+ T cells exhibit a naive phe-
notype in healthy donors.
Pre-sorting T-cell subsets further allowed side-by-side
phenotypic comparisons of WT1-specific CD4+ and
CD8+ T cells in individual donors. Expanded T cells were
antigen-specific in four cases (donors 1, 3, 4, and 5)
(Fig. 4b). Again, WT1-reactive CD8+ T cells were
detected in samples derived from the naive pool but not
from the memory pool (Fig. 4b), confirming the results
obtained by tetramer analysis (Fig. 4a). However, WT1-
reactive CD8+ T cells in donor 3 emerged from both the
naive and memory pools, representing an exception to
the general pattern (Fig. 4c). In contrast to CD8+ T cells,
the highest frequencies of WT1-reactive CD4+ T cells
derived from the memory pool (Fig. 4b,c), confirming
the ex vivo phenotypic analyses (Fig. 2). WT1-specific
CD4+ and CD8+ T cells were also detected in the
unsorted fractions (Fig. 4b).
Taken together, these results confirm the presence of
WT1-reactive CD4+ and CD8+ T cells in the memory and
naive pools, respectively. It is notable that these distinct
phenotypically defined WT1-specific T-cell populations
can coexist in the same individual.
Discussion
In this study, we used cell enrichment strategies to con-
duct an in-depth analysis of the physiological WT1-spe-
cific T-cell repertoire in healthy individuals. The key
findings were: (i) WT1-specific T cells are present in the
vast majority of healthy donors; (ii) WT1-specific CD4+
T cells are commonly present in the memory pool; (iii)
WT1-specific CD8+ T cells reside primarily in the naive
pool; and (iv) WT1-specific memory CD4+ and naive
CD8+ T cells can coexist in the same individual. Collec-
tively, these data imply that distinct mechanisms control
the differentiation of auto-reactive WT1-specific CD4+
and CD8+ T lymphocytes.
The enrichment of WT1-reactive T cells in this study
was based on CD137 up-regulation after in vitro stimula-
tion with pooled WT1 peptides, which results in an oli-
goclonal amplification of WT1-reactive T cells. In these
short-term cultures, both CD4+ and CD8+ T cells
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Figure 4. Phenotypic disparity between CD4+ and CD8+ T cells specific for Wilms’ tumour-1 (WT1). Presorted naive (CD45RA+ CCR7+) or
memory (CD45RO+) T cells or unsorted peripheral blood mononuclear cells (1 9 108 cells each) were stimulated for 36 hr, enriched for
CD137+ cells, and expanded. (a) Representative analysis (donor 4) of WT1 tetramer+ cells after expansion of T cells obtained from presorted
(naive/memory) or unsorted peripheral blood mononuclear cells. Cells were stained with a mixture of HLA-A*0201 tetramers loaded with four
different WT1 epitopes. Plots are gated on CD3+ events. Percentages of tetramer+ cells within the CD8+ T-cell compartment are shown. (b) Intra-
cellular cytokine staining after re-stimulation of expanded cells from a representative individual (donor 4) using either unloaded or differentially
loaded autologous antigen-presenting cells (PTP, peptide pool). (c) Summary of WT1-specific responses for four different donors. Ratios of
naive/memory-derived responses were calculated for WT1-induced tumour necrosis factor-a (TNF-a)-producing CD4+ and CD8+ T cells after re-
stimulation as well as CD8+ tetramer+ T cells.
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produced pro-inflammatory cytokines in response to
WT1 peptides, providing evidence for functional WT1-
specific immunity in healthy donors.
The abundance of functional WT1-reactive CD4+ T
cells was confirmed by enrichment of CD154+ T cells
after short-term antigen-specific stimulation. Based on
this analysis, the calculated prevalence of WT1-specific T
cells ranged from 106 to 105 in the CD4+ cell compart-
ment. These numbers are consistent with published data
for WT1-specific CD4+ T cells quantified using the same
procedure12 and for CD4+ T cells that recognize other
self-derived or neo-antigens, including gp100, fibrinogen,
preproinsulin11 and Bacillus anthracis23, detected by
pHLAII tetramer enrichment. In addition, the ARTE
assay enabled direct ex vivo characterization of WT1-spe-
cific CD4+ T cells in terms of function and phenotype.
Based on this approach, we estimated the presence of
WT1-reactive memory CD4+ T cells in > 60% of healthy
donors. These WT1-specific memory CD4+ T cells readily
produced TNF-a and IFN-c in response to WT1 peptide-
loaded APCs.
In the CD8+ T-cell compartment, calculated frequencies
of WT1-specific T cells ranged from 107 to 105 based
on pHLAI tetramer enrichment studies. Although these
numbers are nearly one order of magnitude below those
estimated for WT1-specific CD4+ T cells, it is noteworthy
that our approach covered only the WT137 epitope rather
than all potentially antigenic regions of the WT1 protein.
Moreover, the frequencies of WT137-specific CD8
+ T cells
reported here are similar to those detected previously for
other self-derived or non-encountered viral antigens,
including NY-ESO-1 (106 to 105) and HIV-1 (107 to
105).10
Our work provides the first direct comparison of CD4+
and CD8+ T cells with the same self-derived antigen spec-
ificity. In this regard, we detected a profound phenotypic
discrepancy between WT1-specific CD4+ and CD8+ T
cells after sorting naive and memory T-cell subsets. WT1-
specific CD4+ T cells were identified in the memory sub-
set, whereas WT1-specific CD8+ T cells arose solely from
the naive pool. This dichotomy contrasts with the classi-
cal model of antigen-specific T-cell memory formation
based on cognate antigen encounter. Alternative mecha-
nisms invoking T-cell homeostasis or cross-reactivity with
other antigens may therefore come into play. On one
side, antigen-specific CD8+ T-cell populations with
memory-like properties can be generated in unexposed
mice by homeostatic expansion.24,25 On the other side,
virus-specific CD4+ T cells in unexposed humans can be
driven into the memory pool as a consequence of cross-
reactivity with common environmental antigens.11 It is
also pertinent to note that low-avidity naive cells might
not be driven into memory and that self-derived antigen-
specific T-cell priming can be inhibited by regulatory
T cells.26,27
Our data imply that memory formation is more com-
mon for WT1-reactive CD4+ T cells than for CD8+ T
cells with the same antigen specificity. Although cross-
reactivity clearly exists within the CD8+ T-cell compart-
ment28–30, we speculate that this phenomenon is the driv-
ing mechanism that generates WT1-specific memory
CD4+ T cells. Cross-reactivity may accordingly be more
common in the CD4+ T-cell compartment and/or the rel-
evant antigens that trigger this process may be more pre-
valent for CD4+ T cells.31,32 Indeed, an in silico database
search identified presumed CD4+ T-cell epitopes derived
from common pathogens that might induce such cross-
reactivity (see Supplementary material, Fig. S3).
In support of our hypothesis, two observations chal-
lenge the concept of ‘virtual memory’ in this instance.
First, WT1-specific CD4+ T cells readily produced effector
cytokines in response to cognate antigen encounter. Sec-
ond, memory cells represented a major subset of the total
WT1-specific CD4+ T-cell population in all healthy
donors. In contrast, the virtual memory T-cell repertoire
typically comprises < 20% of the corresponding antigen-
specific population.24,25
It remains unclear why WT1-reactive T cells are not
negatively selected in the thymus to maintain central tol-
erance against self-derived antigens. Intriguingly, a recent
study reported that truncated versions of the immuno-
dominant Melan-A/MART126-35 epitope are expressed in
human medullary thymic epithelial cells, presumably ren-
dering central tolerance mechanisms incomplete and lead-
ing to high frequencies of naive CD8+ T cells specific for
this antigen in the periphery.33 Genome-wide studies are
currently ongoing to address this possibility for a variety
of other antigens, including WT1.
As the process of clonal deletion to establish central
tolerance is TCR affinity-dependent34, it is reasonable to
assume that WT1-specific T cells engage their target anti-
gens with low or intermediate TCR/pMHC affinities.
However, expanded WT1-specific CD8+ T-cell cultures
displayed functional avidities similar to virus-specific
CD8+ T cells (see Supplementary material, Fig. S4). In
line with this observation, high-affinity donor stem cell-
derived WT1126-specific CD8
+ T-cell clones were used for
adoptive cell therapy in a recent clinical trial.35 Further
support for the therapeutic potential of the natural WT1-
specific T-cell repertoire is based on immune monitoring
studies. Here, the induction of WT1-specific CD8+ T-cell
responses after allogeneic stem cell transplantation and/or
donor lymphocyte infusions demonstrated the immuno-
genicity of WT1 in cancer patients. Moreover, the
induced WT1-specific T cells were probably involved in
mediating graft-versus-leukaemia effects.2–4 Vaccination
strategies, which inevitably rely on mobilization of the
pre-existing WT1-specific T-cell pool, likewise showed
promising results in several clinical studies with response
rates up to 63% in haematological diseases (reviewed in
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ref. 36). We hypothesize that individuals bearing memory
WT1-specific T cells in their blood are able to mount
stronger WT1-specific responses after vaccination and
may therefore benefit most from therapy. It is noteworthy
that the techniques described in this study provide com-
pelling tools for improved, highly sensitive immune mon-
itoring in this context.
In our hands, CD8+ T cells specific for WT137 were
much more abundant than those specific for WT1126
regardless of the enrichment process. This observation
has implications for the design of therapeutic and
immune monitoring strategies, given that many published
studies concentrate solely on CD8+ T-cell clones specific
for WT1126. Vaccination studies that used the WT1126
epitope alone or in combination achieved only limited T-
cell responses in humans.37–39 In contrast, broader WT1-
specific CD4+ and CD8+ T-cell responses were obtained
by approaches incorporating a multitude of WT1-derived
epitopes, such as long peptides40,41 or mRNA-electropo-
rated autologous dendritic cells.42 Consistent with these
findings, WT1-specific CD4+ and CD8+ T cells were read-
ily activated ex vivo by stimulation with pooled WT1 pep-
tides irrespective of HLA genotype. Collectively, these
considerations argue for the therapeutic use of stimuli
that cover the whole WT1 protein, thereby taking advan-
tage of the entire pre-existing pool of WT1-specific T
cells in healthy individuals.
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